KIRAMS / Nagarajan Vinod, 김재형, 임일한*
Abstract
Lanatoside C has a promising anti-tumor activity and is a potential candidate for radiosensitizers. In this study, we have investigated the therapeutic efficacy of the combination of 131I-trastuzumab and lanatoside C for inhibition of human epidermal growth factor receptor 2 (HER2) positive tumor progression in NCI-N87 xenograft model. The combination treatment (131I-trastuzumab and lanatoside C) showed highest cytotoxicity when compared to non-treated control or trastuzumab alone or 131I alone or 131I-trastuzumab alone in vitro. Biodistribution studies using 131I-trastuzumab or combination of 131I-trastuzumab and lanatoside C showed tumor uptake in BALB/c nude mice bearing HER2 positive NCI-N87 tumor xenograft model. The higher tumor uptake was observed in 131I-trastuzumab (19.40 ± 0.04% ID/g) than in the combination of 131I-trastuzumab and lanatoside C (14.02 ± 0.02% ID/g) at 24 h post-injection. Most importantly, an antitumor effect was observed in mice that received the combination of 131I-trastuzumab and lanatoside C (p = 0.009) when compared to control. In addition, mice received lanatoside C alone (p = 0.085) or 131I-trastuzumab alone (p = 0.160) did not significantly inhibit tumor progression compared with control. Taken together, our data suggest that combination of 131I-trastuzumab and lanatoside C might be a potential synergistic treatment for radioimmunotherapy to control the HER2 positive tumor.
Affiliations
Nagarajan Vinod # 1 , Jae Hyung Kim # 2 , Seungbum Choi 2 , Ilhan Lim 3 4 5
1 Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, (KIRAMS), Seoul, 01812, Republic of Korea.
2 Division of RI-Convergence Research, Korea Institute of Radiological and Medical Sciences, (KIRAMS), Seoul, 01812, Republic of Korea.
3 Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, (KIRAMS), Seoul, 01812, Republic of Korea. ilhan@kirams.re.kr.
4 Division of RI-Convergence Research, Korea Institute of Radiological and Medical Sciences, (KIRAMS), Seoul, 01812, Republic of Korea. ilhan@kirams.re.kr.
5 Department of Radiological & Medico-Oncological Sciences, University of Science and Technology (UST), Seoul, 01812, Republic of Korea. ilhan@kirams.re.kr.
# Contributed equally.
편집위원
방사면역치료와 방사선치료 증강제 병합치료가 방사면역치료 효과를 증강시킬 수 있음을 보여준 전임상연구임. 다양한 방사성핵종치료술에도 확장될 수 있는 치료전략임. 방사성핵종치료에 관심이 있는 연구자 및 종양관련 임상가에게 관심을 끌 연구로 생각됨.
2021-07-27 14:49:15
편집위원2
radiosensitizer가 추가된 RIT 치료의 시너지 효과로 방사선 저항성 종양 치료에 임상적으로 기여할 것이라 생각됩니다.
2021-07-27 14:49:41